What AMP® AIM Partners Are Saying

“At AbbVie, we know that tackling the toughest healthcare challenges requires a dynamic and collaborative approach. We are excited to be involved in the next phase of the Accelerating Medicines Partnership program to build a more complete picture of rheumatoid arthritis, lupus, Sjögren’s disease, and other serious autoimmune diseases by implementing innovative technologies like spatial transcriptomics. This collaboration will enable the identification of novel targets and biomarkers to address the unmet needs of people living with autoimmune and immune-mediated diseases.”

“Despite advances in our understanding of inflammatory and autoimmune diseases, there remains unmet need, particularly in identifying patients most likely to benefit from therapeutic interventions. We believe in the power of collaboration and are proud to have participated in the AMP RA/SLE Program to collectively explore difficult medical and scientific questions with the goal of advancing treatments for patients. We are even more pleased to continue this work with the AMP AIM Program by building on the RA/SLE experience and expanding to other important disease areas. We look forward to this partnership and the potential to uncover novel drug targets and precision medicine approaches that will benefit patients across the world.”

“Truly difficult challenges require collaboration and Janssen is proud to support AMP in this next project to unravel the molecular drivers of immune-mediated disorders. This unique collaboration between the NIH, industry partners, and non-profit institutes brings together the necessary talent to unravel the molecular drivers of these devastating diseases and will pave the way for tomorrow’s medicines.”

“The Lupus Foundation of America and National Institutes of Health are committed in their shared goal to reducing the time to an accurate lupus diagnosis and ensuring people with lupus have access to newly targeted and safe treatments. Bold initiatives, like the AMP AIM program, seek to discover the causes of inflammation and clinical disease, and hold the promise for addressing the significant unmet need for people living with lupus and other autoimmune diseases.”

“The Lupus Research Alliance is proud to be part of AMP-AIM which will enable unprecedented disease characterization and novel target identification for lupus and related diseases. This important program builds on the pioneering discoveries of AMP RA/SLE and will provide further insights into disease mechanisms as well as critical clinical data sets and research tools to accelerate the development of novel therapies for individuals with lupus.”

“The National Psoriasis Foundation is looking forward to the insights and answers generated by this next generation public-private partnership. The more than 8 million people in the U.S. living with psoriasis or psoriatic arthritis – systemic immune-mediated diseases associated with inflammation throughout the body – will benefit greatly from the discovery of new treatment targets and mechanisms. We celebrate this potential of the AMP AIM partnership to help achieve a world free from the burdens of psoriatic disease.”

“Autoimmune diseases can be debilitating, disfiguring and distressing, dramatically affecting patients’ day-to-day lives. We are pleased to continue our partnership through AMP AIM to accelerate the discovery of innovative treatments and ultimately improve the lives of our patients.”

“We are excited to be part for the new AMP AIM program in immunological diseases. In the last 6 years the Accelerating Medicine Partnership has delivered valuable insights into the molecular and cellular mechanisms of Rheumatoid Arthritis and Systemic Lupus Erythematosus at single cell resolution. Building on these achievements, AMP AIM will help to understand shared and unique molecular mechanisms in a range of inflammatory diseases and will support our mission to deliver life changing medicines for the benefit of patients.”

“Sjögren’s is a systemic autoimmune disease that is frequently misunderstood and underdiagnosed. We are extremely proud to join the AMP AIM project as a Steering Committee member alongside the NIH, other disease advocacy organizations and pharmaceutical companies. AMP AIM offers a new way to tackle the formidable barriers that have prevented us from fully understanding Sjögren’s and will potentially uncover mysteries so we can better diagnose and treat Sjögren’s patients in the future.”

“The Arthritis Foundation is excited to continue being a stakeholder in the Accelerating Medicines Partnership (AMP). We are looking forward to contributing to the important work that will be done by the Autoimmune and Immune-Mediated Diseases Program, or AMP AIM. This collaborative research will further accelerate the validation of specific drug targets in autoimmune diseases that share immune and inflammatory pathways. It will facilitate both therapeutic development and data sharing through a knowledge portal, and further our Foundation’s mission of improving the lives of patients with various forms of arthritis, including rheumatoid arthritis.”

“UCB is proud to partner with the Foundation for the National Institutes of Health for their AMP Autoimmune and Immune-Mediated Diseases initiative. By leveraging state of the art technology and novel analytics to improve our understanding of tissue level cellular function, and its role in inflammation and clinical disease, this research will advance our understanding of costly diseases that place a high burden on patients, including disease progression from psoriasis to psoriatic arthritis, disease phenotypes and systemic lupus erythematosus (SLE). These collaborations are critical for speeding the development of innovative therapies that can significantly improve patients’ lives,’’

“At Visterra, we believe that collaboration will be essential in successfully addressing and solving many of the great challenges of complex diseases. In joining AMP AIM, we are excited about the opportunities to partner with NIH, industry and non-profits and the possibilities of accelerating research, improving disease understanding and developing technologies to help create new medicines to improve the lives of patients.”